MFA Certifies First MulteFire Device and Base Station to Enable Private Networks in Unlicensed Spectrum
9.9.2021 17:43:00 EEST | Business Wire | Press release
MFA, an international organization championing the global industry adoption of private networks, is gaining industry momentum with the recent certification of the Nokia Industrial MulteFire fieldrouter 700 and announcement of Uni5G Technology Blueprints. The Nokia MulteFire solution, which is available for deployment with Nokia Digital Automation Cloud, will enable MulteFire LTE-based private network adoption worldwide, unlocking access to unlicensed spectrum. With deployment available globally, it can be used by small and medium enterprises without access to licensed spectrum and it can bring additional capacity as a complementary layer to wireless networks and enable new nomadic use cases to advance Industry 4.0.
In addition to supporting 4.9G/LTE private networks, MFA recently announced its expansion to 5G with Uni5G Technology Blueprints, which help provide guidance to enterprises looking to deploy 5G private networks. MFA is also developing best practices and targeted guides to help industry verticals implement the key 3GPP 5G specification features that are relevant to their specific deployment.
The MFA Certification Program ensures that devices have implemented the MulteFire specifications correctly and are able to interoperate with devices from other manufacturers.
“The Nokia MulteFire solution has passed rigorous interoperability testing at our Authorized Test Lab DEKRA,” said Scott Fischel, MFA Certification Group Chair. “We congratulate Nokia on delivering the world’s first MulteFire Certified end-to-end solution that will provide end-users with confidence that it can meet the robust connectivity requirements offered by MulteFire 4.9G/LTE private wireless.”
“Private 5G and LTE networks are a rapidly growing market and will account for over $5B in global enterprise expenditure by 2025,” said Pablo Tomasi, Principal Analyst, Private Networks, Omdia. “MFA aims to support and accelerate the private 5G networks market through both this certification program and by tackling the issue of replicability and complexity through the delivery of Uni5G Technology Blueprints developed to simplify deployment for different industry verticals.”
The MFA Certification Program is available to MFA members, and it will help facilitate further expansion of the MulteFire private wireless ecosystem. For companies interested in joining the MFA, visit www.mfa-tech.org/become-a-member.
Resources:
- Interview: Meet MFA Certificate Authority
- Interview: Meet MFA Authorized Test Lab – DEKRA
- Video: Uni5G and MulteFire Private Networks for Manufacturing
- Press Release: MulteFire Alliance (MFA) Simplifies Path to 5G Private Network Deployment for Enterprise
- White Paper: “5G Private Networks for Maritime Use Opportunities for Digital Port Automation,” Beecham Research
- White Paper: “The Importance of Spectrum Liberalization for Private 5G Networks,” ABI Research
About MFA
MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005742/en/
Contact information
MFA
Lori Mesecke, +1-503-459-9150
press@multefire.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom